This is an archive of papers published by the staff and faculty of Fox Chase Cancer Center. For questions about content, please contact Talbot Research Library
Last updated on
Weiss GJ , Langer C , Rosell R , Hanna N , Shepherd F , Einhorn LH , Nguyen B , Paul S , McAndrews P , Bunn PA , Kelly K
Elderly patients benefit from second-line cytotoxic chemotherapy: A subset analysis of a randomized phase III trial of pemetrexed compared with docetaxel in patients with previously treated advanced non-small-cell lung cancer
JOURNAL OF CLINICAL ONCOLOGY. 2006 Sep;24(27) :4405-4411
URL: http://gateway.isiknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=Alerting&SrcApp=Alerting&DestApp=WOS&DestLinkType=FullRecord;KeyUT=000240708200008*Order Full Text [ ]
AbstractPurpose Numerous prospective and retrospective studies have concluded that elderly patients ( 70 years old) achieve a similar survival benefit, with acceptable toxicity, from first-line cytotoxic chemotherapy for the treatment of advanced non-small-cell lung cancer (NSCLC) compared with their younger counterparts. However, few published data exist on the efficacy and tolerability of second-line cytotoxic therapy in this population. Patients and Methods Retrospective analysis of a large second-line trial was performed. Data from 571 patients randomly assigned to docetaxel 75 mg/m(2) or pernetrexed 500 mg/m(2) every 3 weeks were analyzed for efficacy and toxicity comparisons between age groups and treatment arms. Results Eighty-six of 571 patients (15%) were 70 years old, similar to rates of elderly observed in the first-line setting. Elderly patients receiving pemetrexed (n = 47) or docetaxel (n = 39) had a median survival of 9.5 and 7.7 months compared with 7.8 and 8.0 months for younger patients receiving pemetrexed (n = 236) or docetaxel (n = 249), respectively. Elderly patients treated with pemetrexed had a longer time to progression and a longer survival than their counterpart patients treated with docetaxel (not statistically significant). Febrile neutropenia was less frequent in elderly patients treated with pemetrexed (2.5%) compared with docetaxel (19%; P =.025), with only one death as a result of toxicity (docetaxel arm). Conclusion Elderly patient participation was similar to rates observed in the first-line setting. There was no E. significant difference in outcome or toxicity between elderly and younger patients. For elderly patients with advanced NSCLC and good performance status, second-line cytotoxic therapy is appropriate. In this subset, pernetrexed produced a more favorable toxicity profile.